JUDY NEWMAN , 608-252-6156 Aug 31, 2014 Aug 31, 2014 0 Exact Sciences’ spanking clean, new labs in the Novation Campus, off Rimrock Road, sit waiting for the rush to begin. Their mission: to examine ...
Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.
The FDA has approved the Cologuard Plus test for colorectal cancer screening in adults aged 45 years at average risk for colorectal cancer. The Food and Drug Administration (FDA) has approved the ...
The Cologuard Plus test is more accurate than the original Cologuard, and should be easier to mail in for stool analysis. The newest version of Cologuard, an at-home colon cancer screening test, ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
What if you didn't have to get a colonoscopy every decade from ages 45 to 75? No, this isn't an excuse to skip screening for colon cancer, which has been proven to save lives. But there are several ...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance access to colorectal cancer (CRC) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback